and 144. Urin were collcted at intervals of 12 h, from hour 0 to hour 156. At least five samples were withdrawn after infusion (from hour 108 to hour 168) in five patients following either schedule A or B. Eeven patients followed schedule A, four schedule B and two patients followed both schedules.
. Results concerning the kinetics of DOX modulated by VER are controversial (Kerr et al., 1986) . The purpose of the present study was to verify the possible variation in the kinetics of DOX concurrently mini with VER, infuse at escalating dose rates throughout the DOX infusion. F ting dose rates of VER infusion were plann to prevent sudden cardiovascular toxicity resulting from the required, high VER concentration. The prolonged infusion of DOX was seleted because it offers, at kast in vitro (Lai et al., 1991) (Salama et al., 1989) . Sampling of blood to measure VER and nor-VER concentration was performed in all patients, at least in the first course, at the following times: hours 0, 12, 24, 36, 48, 60, 72, 84, 108, 132, 144 and 156. Phamacokietic anaysis In order to study the systm at steady state (SS), a linear one-compartment model was adopted. Rate of infusion (k0) was calculated as:
where C. is the target steady-state concentration (M/V) and Cl is the apparent systemic clearance (Vlt) (mean value reported in the literature; Benet and Widliams, 1990 The distribution of DOX in the body is much faster than elimination (Speth et al., 1988) , thus the post-infusion curve should very quickly approach the elimination phase curve. Since the elimination of DOX is a first-order process and the reported, final half-life of elimination is 30 h, three samples were sufficient to estimate the constant of elimination (Eksborg et al., 1985) . Individual ranges of variation of C., in different courses are reported (Table I ) only for the patients who underwent several courses with schedule B, while most patients following schedule A performed only one course. PCNONLIN version 4.0 was the non-linear regression program used to estimate kinetic parameters defining the model. Statistical analysis t-Tests for unpaired samples, with superimposable variability, were performed to compare estimates of kinetic parameters from groups of patients following different treatments.
Results
The observed C. was 23 ± 7ngml' (range 15-34ngml1) for patients following schedule A (C3A) while the calculated C. was 24 ng ml-I (Table II) Table II . VA was 21 ± 51 kg-' (range 16-27), VB was 20± 61 kg-' (range 17-31) and VL was 25 1 kg-(range 9-66); tiA was 20 ± 8 h (range 14-32), tjB was 23 ± 5 h (range 16-29) and tlL was 30 h (range 14-37); CIA was 13 ± 4 ml min' kg' (range 10-21), CIB was 13 ± 2mlmin-'kg-' (9-16) and ClL was 13 ml min' kg-' (range [8] [9] [10] [11] [12] [13] [14] [15] [16] . The fractions of DOX excreted in the urine (fu) were 9 ± 3% (A) and 7 ± 2% (B).
Individual parameters ranged from 3.7 to 11.2%. Estimates of our study fell within the range reported in the literature (fu < 15%) (Speth et al., 1990) . Estimates of treatments A and B were compared with each other and with reported estimates (Benet and Williams, 1990) : no significant difference (P >0.6) was found. On average, VER peak level was 1,650ngmml-' (ranging from 620 to 2,560 ng ml-') and serum concentrations of nor-VER, a metabolite active as a chemosensitiser, were 590 ng ml-' (ranging from 210 to 960 ng ml-').
Cardiovascular side-effects were limited and rapidly reversible after the completion of VER infusion. Data referred to 15 courses performed in nine patients. Prolonged QT was observed in 15 courses (15/15); other side-effects were junctional rhythm (9/15), first-degree block (4/15) and seconddegree block (1/15). No hypotension (mean arterial pressure <80 mmHg) or congestive heart failure was observed. No patient had hyperbilirubinaemia.
Discussion
The association of antineoplastic agents and RMAs requires investigation of the possible kinetic variations in the drugs resulting from their interaction. The few data available on the interaction between VER and anthracyclines are controversial. A significant increase in the half-life of elimination of DOX was found when DOX was co-administered with VER (oral dose), but other kinetic parameters related to elimination did not differ significantly (Kerr et al., 1986) . (ng ml-') (ng ml-') (I kg-') (h) ( were limited and reversible, so possible variations in the pharmacokinetic parameters owing to impaired haemodynamics were excluded. (4) No borderline P-value was found comparing kinetic parameters. In conclusion, VER does not appear to modulate DOX kinetics. These data should be considered in the design of further schedules combining DOX with VER and the evaluation of the response and toxicity determined by these treatments to overcome MDR.
